STOCK TITAN

LIFECORE BIOMEDICAL DE (LFCR) SEC Filings

LFCR NASDAQ
Rhea-AI Summary

Lifecore Biomedical, Inc. (LFCR) is the issuer whose common shares are covered by an amended ownership report. Greenhaven Road Investment Management, L.P., MVM Funds LLC and Scott Miller each reported beneficial ownership of 2,868,881 shares, or 7.6%, with shared voting and dispositive power, as of September 30, 2026.

Greenhaven Road Capital Fund 1, L.P. reported 1,518,411 shares, or 4.0%, and Greenhaven Road Capital Fund 2, L.P. reported 1,350,470 shares, or 3.6%. The reporting persons disclaimed beneficial ownership except to the extent of their pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
ownership
-
Rhea-AI Summary

Lifecore Biomedical, Inc. (LFCR) agreed to be acquired through a merger in which Hazel Merger Sub, Inc. would merge into Lifecore, leaving Lifecore a wholly owned subsidiary of Lifecore Inc., an affiliate of Webster Equity Partners. If completed, each eligible common share would convert into $6.28 in cash, without interest, plus one contingent value right (CVR). Series A preferred shares would receive the cash Conversion Amount plus a CVR for each underlying common share; as of September 27, 2026, the amount was $6.53 per underlying common share.

CVRs may pay milestone amounts, if any, under the CVR agreement. Stockholders are scheduled to vote December 23, 2026; approval requires a majority of the combined voting power of outstanding common and Series A shares on an as-converted basis, and the board recommends FOR all three proposals. The HSR waiting period ended early on November 4, 2026. Parent anticipates approximately $550 million in funds at closing, including $400 million in equity commitments, $115 million in term-loan commitments from two lenders, a $30 million revolving facility, and a $35 million term loan from Alcon Research, LLC. Completion is not subject to a financing condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
proxy
-
Rhea-AI Summary

Lifecore Biomedical, Inc. (LFCR) reported that the Department of Justice and Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act, effective November 4, 2026, satisfying that merger-closing condition. Under the September 27, 2026 merger agreement, Hazel Merger Sub, Inc. is to merge into Lifecore Biomedical, with the company surviving as a wholly owned subsidiary of Lifecore Inc. (Parent).

The proposed merger remains subject to the other closing conditions and approvals, including adoption of the merger agreement by Lifecore Biomedical stockholders at a special meeting. The company has filed a preliminary proxy statement and intends to file a definitive proxy statement for the meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
current report
Rhea-AI Summary

Lifecore Biomedical, Inc. (LFCR) reported third-quarter revenue of $25.322 million, down 19% from $31.109 million, and net loss of $40.084 million versus $9.991 million. Nine-month revenue was $82.682 million, down 22% from $105.686 million, and net loss was $61.220 million versus $20.934 million.

On September 27, 2026, Lifecore agreed to merge with affiliates of Webster Equity Partners. At the effective time, each common share outstanding other than excluded shares is to be canceled for $6.28 in cash, without interest, plus one contingent value right (CVR), which carries rights to milestone payments if and when payable. Each Series A preferred share is to receive its defined Conversion Amount in cash plus one CVR for each common share into which it is convertible. Closing is expected at the end of 2026, subject to stockholder and regulatory approvals and other conditions.

As of September 30, 2026, Lifecore had $23.035 million of cash and approximately $201.3 million of indebtedness with Alcon. Redemption notices covered all 50,187 preferred shares, with payment scheduled for December 28, 2026; internally generated cash is not expected to fund all or any significant redemptions by then. Disclosure controls were not effective because a material weakness remained unremediated.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
quarterly report
-
Rhea-AI Summary

Lifecore Biomedical, Inc. (LFCR) reported third-quarter 2026 revenue of $25.3 million, down 18.6% from $31.1 million a year earlier, and a net loss of $40.1 million versus $10.0 million. Gross profit was $6.8 million, compared with $7.8 million. The company recorded a $31.270 million loss from the change in fair value of its related-party debt derivative liability, versus $0.375 million a year earlier. Adjusted EBITDA, a non-GAAP measure, increased to $4.0 million from $3.1 million.

For the first nine months, revenue was $82.7 million, down 21.8%, and net loss was $61.2 million versus $20.9 million; Adjusted EBITDA was $13.6 million versus $21.1 million. Operating cash flow was $9.5 million and free cash flow was $6.914 million. Quarter-end liquidity was approximately $38.0 million, including $23.0 million in cash and $15.0 million in revolving credit availability. Lifecore secured two technology-transfer projects in the quarter and three development-phase programs early in the fourth quarter, including one Phase 2 and two Phase 3 products. It expects the two technology-transfer projects to contribute to long-term revenue growth objectives beginning in 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
current report
-
Rhea-AI Summary

Lifecore Biomedical, Inc. (LFCR) agreed on September 27, 2026, to merge with Hazel Merger Sub, Inc.; Lifecore would survive as a wholly owned subsidiary of Lifecore Inc., an affiliate of Webster Equity Partners. If completed, each eligible common share would convert into $6.28 in cash, without interest, plus one contingent value right (CVR). A CVR may pay milestone amounts, if and when payable. Each Series A preferred share would receive cash equal to its Conversion Amount plus one CVR for each common share into which it is convertible; as of September 27, 2026, the Conversion Amount equaled $6.53 per convertible common share.

The board unanimously recommends a vote FOR the merger agreement proposal. Completion requires approval by holders of a majority of the combined voting power of common and preferred shares and satisfaction of other closing conditions; the merger agreement has no financing condition. Parent anticipates approximately $550 million in funds at closing, including a $400 million equity commitment and debt commitments. Voting agreements cover approximately 27.34% of combined voting power as of the record date. After completion, stockholders would no longer own shares of the surviving corporation; the Company agreed to use reasonable best efforts to delist and deregister its common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
proxy
Rhea-AI Summary

Lifecore Biomedical, Inc. (LFCR) set November 4, 2026, as the record date for a special stockholder meeting to consider, among other matters, adoption of the Agreement and Plan of Merger entered into on September 27, 2026, with Lifecore Inc. and Hazel Merger Sub, Inc., and approval of the merger contemplated by the agreement. Stockholders of record at the close of business on the record date will be entitled to notice of and a vote at the meeting.

Lifecore Biomedical will file a preliminary proxy statement and intends to file a definitive proxy statement for the meeting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
-
Rhea-AI Summary

Lifecore Biomedical, Inc. is party to a merger agreement providing, subject to its terms and conditions, for Hazel Merger Sub, Inc., a wholly owned subsidiary of Lifecore, Inc., to merge into Lifecore Biomedical, with Lifecore Biomedical surviving. On September 27, 2026, the Wynnefield reporting persons, including Nelson Obus and Joshua Landes, co-managing members of Wynnefield Capital Management, LLC, entered a Voting and Support Agreement; its execution did not involve an acquisition or disposition of common stock.

The reporting persons agreed to vote their Covered Shares for the merger and related transactions and against certain competing acquisition proposals. They also agreed to support certain adjournment or postponement proposals and cause their shares to be present for a quorum. Transfers are restricted, subject to specified permitted transfers generally conditioned on the transferee agreeing to be bound, and the reporting persons waived appraisal rights, subject to the agreement's terms.

The reporting persons may be deemed to beneficially own 5,512,211 shares, approximately 14.3% based on a denominator of 38,497,455 shares; the aggregate includes 644,395 shares issuable upon conversion of Series A Preferred Stock. Three Wynnefield entities delivered notices on June 30, 2026 to redeem all Series A Preferred Stock they held.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
ownership
-
Rhea-AI Summary

Lifecore Biomedical, Inc. said its subsidiary Lifecore Biomedical, LLC amended its contract manufacturing agreement with Alcon Research, LLC, effective November 1, 2026. The amendment extends the Initial Term from December 31, 2031 to December 31, 2034 and provides for automatic renewal in successive 24-month periods unless either party gives proper notice.

The amendment also establishes Alcon’s minimum purchase obligations through 2034 and certain supply obligations of Lifecore. Beginning November 1, 2026, Lifecore agreed not to enter new agreements to develop, supply or manufacture certain products that directly compete with certain Alcon products. The restriction does not limit performance under agreements existing before that date, or their renewal, extension, amendment or replacement on substantially similar terms or terms more favorable to Lifecore.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
current report
Rhea-AI Summary

Lifecore Biomedical, Inc. agreed to a merger in which Hazel Merger Sub, Inc. will merge into the issuer, which will survive as a wholly owned subsidiary of Lifecore Inc. Each eligible common share is to receive $6.28 in cash and one contingent value right (CVR). Series A preferred shares are to receive cash based on the defined Conversion Amount plus one CVR for each common share into which they are convertible.

Closing is subject to the issuer stockholder vote, expiration or termination of the Hart-Scott-Rodino waiting period, other required governmental consents, registrations, notices or approvals, and the absence of a legal restraint. The reporting persons agreed not to transfer covered shares and to vote for the merger and against specified competing proposals. The voting agreement ends upon the earliest of the required vote, the merger’s effective time, termination of the merger agreement, or a qualifying adverse board recommendation.

Legion Partners Asset Management reported beneficial ownership of 6,991,719 shares, approximately 17.3%. Legion Partners Holdings, Christopher S. Kiper and Raymond White each reported 6,991,919 shares, approximately 17.3%, through overlapping attribution. Kiper and White are identified as managing directors of Legion Partners Asset Management and managing members of Legion Partners Holdings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
ownership

FAQ

How many LIFECORE BIOMEDICAL DE (LFCR) SEC filings are available on StockTitan?

StockTitan tracks 53 SEC filings for LIFECORE BIOMEDICAL DE (LFCR), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for LIFECORE BIOMEDICAL DE (LFCR)?

The most recent SEC filing for LIFECORE BIOMEDICAL DE (LFCR) was filed on November 16, 2026.